open access

Vol 4, No 6 (2015)
Review articles (submitted)
Published online: 2016-02-22
Get Citation

Cardiovascular safety of dipeptidyl peptidase-4 (DPP-4) inhibitors

Janusz Gumprecht
DOI: 10.5603/DK.2015.0027
·
Clinical Diabetology 2015;4(6):238-242.

open access

Vol 4, No 6 (2015)
Review articles (submitted)
Published online: 2016-02-22

Abstract

Incretin-based agents, called gliptins or dipeptidyl peptidase-4 inhibitors (DPP-4), are currently considered a promising therapeutic option. It has been known for a long time that these drugs effectively improve glycaemic control, which is reflected by significant HbA1c reduction, without increasing the rate of hypoglycaemia or body weight gain, and that they do not have significant adverse effects. Is it, however, enough to consider them as ‘safe’? No, certainly not. Currently, when assessing the safety of glucose-lowering drugs, the effect on cardiovascular system must be also (and first of all) taking into account. Except for glucose-lowering activity, gliptins have multiple pleiotropic effects and, additionally, are safe in terms of cardiovascular risk, which was proved based on the results from large clinical trials such as SAVOR-TIMI, EXAMINE and, the most recent, TECOS. The future will show whether long-term follow-up of patients treated with gliptins and the results of further trials will confirm current knowledge about DPP-4 inhibitors and expectations associated with this class of drugs.

Abstract

Incretin-based agents, called gliptins or dipeptidyl peptidase-4 inhibitors (DPP-4), are currently considered a promising therapeutic option. It has been known for a long time that these drugs effectively improve glycaemic control, which is reflected by significant HbA1c reduction, without increasing the rate of hypoglycaemia or body weight gain, and that they do not have significant adverse effects. Is it, however, enough to consider them as ‘safe’? No, certainly not. Currently, when assessing the safety of glucose-lowering drugs, the effect on cardiovascular system must be also (and first of all) taking into account. Except for glucose-lowering activity, gliptins have multiple pleiotropic effects and, additionally, are safe in terms of cardiovascular risk, which was proved based on the results from large clinical trials such as SAVOR-TIMI, EXAMINE and, the most recent, TECOS. The future will show whether long-term follow-up of patients treated with gliptins and the results of further trials will confirm current knowledge about DPP-4 inhibitors and expectations associated with this class of drugs.

Get Citation

Keywords

DPP-4, cardiovascular safety, type 2 diabetes

About this article
Title

Cardiovascular safety of dipeptidyl peptidase-4 (DPP-4) inhibitors

Journal

Clinical Diabetology

Issue

Vol 4, No 6 (2015)

Pages

238-242

Published online

2016-02-22

DOI

10.5603/DK.2015.0027

Bibliographic record

Clinical Diabetology 2015;4(6):238-242.

Keywords

DPP-4
cardiovascular safety
type 2 diabetes

Authors

Janusz Gumprecht

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl